Ivonescimab, a Closely Watched Lung Cancer Drug From China, Rejected by FDA Without Significant Survival Gain

The Food and Drug Administration has declined to approve ivonescimab, a closely watched lung cancer drug first developed in China, for patients with advanced EGFR-mutated non-small cell lung cancer, Summit Therapeutics announced Nov. 15. The FDA issued a complete response letter saying the application “cannot be approved in its present form,” according to Summit’s filing with the Securities and Exchange Commission.

According to Summit, the FDA concluded that a delay in cancer growth was not enough without a statistically significant improvement in overall survival. The letter itself has not been made public.

For patients whose lung cancer has grown after targeted pills, the decision closes a hoped-for new option, at least for now. It also sends a clear message about the evidence the FDA expects in this setting: proof that patients live longer, not only that tumors are held back.


The FDA’s Reasoning, According to Summit

Summit had sought approval for ivonescimab with platinum-based chemotherapy for locally advanced or metastatic non-small cell lung cancer in patients previously treated with an EGFR tyrosine kinase inhibitor, a type of targeted pill. The FDA’s decision date was Nov. 14.

The company said the FDA determined that “substantial evidence of effectiveness is not established in the absence of a statistically significant overall survival” benefit, in its Nov. 15 company announcement. The agency also said a progression-free survival benefit alone did not support a positive balance of benefits and risks.

A complete response letter is not a permanent ban. Companies can meet with the FDA, run new studies or resubmit with additional data, though that typically takes months or years.

Because the full letter has not been released, the FDA’s complete reasoning, including any comments on safety, manufacturing or trial conduct, is not known. Summit did not describe a resubmission plan, but said it will continue other trials of the drug.

“We are disappointed for patients and their families awaiting additional treatment options in this setting,” said Robert Duggan, Summit’s chairman and chief executive.


A Drug That Blocks Two Targets at Once

Ivonescimab is a bispecific antibody that blocks two targets in a single molecule. One is PD-1, the immune checkpoint targeted by drugs such as Keytruda. The other is VEGF, a protein tumors use to build blood vessels.

The drug was developed by China’s Akeso, which licensed rights in the United States and other markets to Summit. It has drawn wide attention after Chinese trials reported strong results, including one in which it outperformed Keytruda on progression-free survival.


HARMONi Trial Results

The application rested on HARMONi, a double-blind phase 3 trial of 438 patients randomly assigned to ivonescimab or placebo, each with chemotherapy. All had nonsquamous lung cancer with EGFR mutations that had progressed after EGFR-targeted pill treatment.

Ivonescimab extended median progression-free survival to 6.8 months, compared with 4.4 months on chemotherapy alone, CancerNetwork reported. At 12 months, 25.4% of patients on ivonescimab had no cancer progression, compared with 8.3% on chemotherapy alone. Dr. Jonathan Goldman of UCLA, who presented the results, said the benefit was “consistent across subgroups.”

The survival gap is the problem. Overall survival, a co-primary goal, showed a positive trend at the primary analysis in April 2025, with a hazard ratio of 0.79 and a p-value of 0.057. The trial’s statistical plan required a p-value of 0.0448 to declare a survival win at that analysis, Summit said in 2025.

Later analyses looked better but could not fix that result. Among Western patients, the survival hazard ratio improved from 0.98 at the primary analysis to 0.76 at a June 2026 data cut, matching the full trial, but it was not statistically significant, Fierce Pharma reported. Trials must meet their prespecified survival test at the planned analysis, and later looks carry less statistical weight.

Severe immune-related side effects occurred in 9.6% of patients on ivonescimab versus 6.0% on placebo. The most common immune-related effects were thyroid problems and higher liver enzymes.


Options for Patients With EGFR-Mutated Lung Cancer

EGFR mutations are more common in people who have never smoked, women, and people of Asian descent. Most patients start with a targeted pill, but the cancer usually develops resistance over time.

That makes the setting HARMONi tested a common and difficult one. Patients who reach this point have often been on targeted therapy for a year or more and may be weighing chemotherapy for the first time, along with its effects on work, family, and daily life. The FDA decision means U.S. patients in this situation will not have ivonescimab as an approved option for now.

Patients whose cancer has progressed on osimertinib or another targeted pill still have FDA-approved options, including chemotherapy and other targeted combinations, depending on their tumor’s genetic profile. Patients can ask their oncologist whether repeat biopsy or blood testing could reveal new mutations that open other treatments.

People interested in ivonescimab can ask whether clinical trials are enrolling nearby, since Summit is running other studies of the drug, including HARMONi-3 and HARMONi-7. Cancer centers can help with eligibility, travel, and cost questions.

New or worsening shortness of breath, coughing up blood, severe headache or confusion should be reported to the care team quickly. No one should stop current treatment without talking with their oncologist. MedicalDaily will report if Summit releases the full letter, announces a new filing, or reports results from other trials.



Key Questions Answered

What did the FDA decide? It issued a complete response letter, declining to approve ivonescimab with chemotherapy for EGFR-mutated lung cancer after targeted pills.

Why? Summit said the FDA found that a progression-free survival benefit was not enough without a statistically significant survival improvement.

Is the FDA letter public? No. The reasons come from Summit’s statement and SEC filing.

What did the trial show? Median progression-free survival of 6.8 months versus 4.4 months, but overall survival missed statistical significance.

Who developed ivonescimab? China’s Akeso, which licensed U.S. rights to Summit Therapeutics.

What options remain for patients? Chemotherapy, other targeted combinations based on tumor testing, and clinical trials.

Published by Medicaldaily.com


Source link

Related Articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Stay Connected

0FansLike
3,912FollowersFollow
22,900SubscribersSubscribe
- Advertisement -6000 PLR EBOOKS

Latest Articles